Amicus Therapeutics is a biotechnology company that creates treatments for unique diseases of today. They specialize in treating specially genetic diseases. Amicus Therapeutics’ products are used throughout the nation. The company was founded in 2002. However, Amicus Therapeutics announced themselves to the public in 2007. The main location for Amicus Therapeutics is in the city of New Jersey. The company also has another office in San Diego that has been open since 2008.
Amicus Therapeutics’ company has about 50-100 professionals on staff. This company is top-of-the-line because they have some of the best clinical professionals working to find treatments for rare diseases. The chairman of Amicus Therapeutics is John Crowley. He has been with the company since 2005. Crowley has publicly said that he is very proud of his team for all of their hard work. He is happy to have a great team that is very persistent in helping others. Amicus Therapeutics is a well trusted company because they let their patients see that they have strong ethics. Patients have grown to genuinely love and appreciate Amicus Therapeutics!
Amicus Therapeutics has a large support system. They have received different grants for research from several different organizations. For example, they received grants from the Alzheimer’s foundation and the Michael Fox Foundation as well. Many people have been willing to support Amicus Therapeutics because they are doing a good deed by trying to find treatments for all of these rare conditions. Follow Amicus Therapeutics on twitter.com.
Recently, Amicus Therapeutics has developed migalastat which is used to treat patients with Fabry. Fabry is a rare genetic disease in which individuals have a deficiency of enzymes. They have also developed SD-101 which is a therapy to treat Epidermolysis Bullosa, a tissue disorder. Amicus Therapeutics has been working extremely hard to treat patients with these rare genetic disorders. The public cannot wait to see what else Amicus Therapeutics has in store for their patients! Visit Market Watch to know more about Amicus Therapeutics.